Back to the article

HealthRX.com · Printable medication review sheet

Ozempic stop plan and glucose log

Fill this in with your prescriber before a planned last dose: why and when you are stopping, which medicine will cover your blood sugar, and a log of glucose and weight for the weeks after, with the label's stop-now warnings alongside.

Companion to “Ozempic: How to Safely Stop (Discontinuation Protocol)” · healthrx.com/ozempic/discontinuation-protocol · Facts checked 2026-10-18

Your stop

Reason for stopping
Date of the last Ozempic dose
Dose at the last injection (mg)
Most recent HbA1c and its date
Medicine that will take over, and its start date
Date of the next HbA1c check

After the last dose

DateFasting glucoseWeightAppetite or symptomsNotes

From the Ozempic label and the shortage data

  • Semaglutide stays in the circulation for about 5 weeks after the last dose; its half-life is about 1 week.[1]
  • Planning a pregnancy: stop Ozempic at least 2 months beforehand.[1]
  • While on Ozempic, insulin or a sulfonylurea carries a higher risk of low blood sugar; ask how those doses should change once it is stopped.[1]
  • Shortage study: mean HbA1c rose from 7.0% to 8.1% within 3 months after stopping dulaglutide, another weekly GLP-1 drug.[2]

Stop and get help now for

  • Persistent or severe stomach pain, sometimes spreading to the back, with or without vomiting.[1]
  • Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing.[1]

Questions before the last dose

  1. Which medicine will cover my blood sugar, and when does it start?
  2. How often should I check glucose in the first weeks?
  3. When is my next HbA1c?
  4. If I want to restart later, how would we do it?
Sources for the facts on this sheet
  1. Novo Nordisk, via DailyMed. Ozempic (semaglutide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-06-01. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. Choe HJ, Nauck MA, Moon JH, et al. Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes. Endocrinol Metab (Seoul) 2025. PMID 39582250. https://pubmed.ncbi.nlm.nih.gov/39582250/

This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.